INHIBITION OF DEGRADATION OF EXTRACELLULAR MATRIX

PROBLEM TO BE SOLVED: To provide an agent to be used for a treatment of conditions associated with extracellular matrix degradation such as insulitis or autoimmune Type-1 diabetes, in particular, used for improving transplantation outcomes for the treatment of insulitis or Type-1 diabetes.SOLUTION:...

Full description

Saved in:
Bibliographic Details
Main Authors ZIOLKOWSKI ANDREW, PARISH CHRISTOPHER RICHARD, SIMEONOVIC CHARMAINE
Format Patent
LanguageEnglish
Published 24.10.2013
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide an agent to be used for a treatment of conditions associated with extracellular matrix degradation such as insulitis or autoimmune Type-1 diabetes, in particular, used for improving transplantation outcomes for the treatment of insulitis or Type-1 diabetes.SOLUTION: An agent for inhibiting degradation of a heparan sulfate proteoglycan in an extracellular matrix associated with islet beta cells is used. A method is provided, including a stage of bringing the extracellular matrix into contact with an effective amount of a heparanase inhibitor.
Bibliography:Application Number: JP20130128065